89 related articles for article (PubMed ID: 1622625)
1. The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs.
Leonessa F; Boulay V; Wright A; Thompson EW; Brünner N; Clarke R
Acta Oncol; 1992; 31(2):115-23. PubMed ID: 1622625
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.
Brünner N; Boulay V; Fojo A; Freter CE; Lippman ME; Clarke R
Cancer Res; 1993 Jan; 53(2):283-90. PubMed ID: 8380254
[TBL] [Abstract][Full Text] [Related]
3. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression.
Clarke R; Skaar T; Baumann K; Leonessa F; James M; Lippman J; Thompson EW; Freter C; Brunner N
Breast Cancer Res Treat; 1994; 31(2-3):237-48. PubMed ID: 7881102
[TBL] [Abstract][Full Text] [Related]
4. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells.
Thompson EW; Brünner N; Torri J; Johnson MD; Boulay V; Wright A; Lippman ME; Steeg PS; Clarke R
Clin Exp Metastasis; 1993 Jan; 11(1):15-26. PubMed ID: 8380760
[TBL] [Abstract][Full Text] [Related]
5. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
6. Hormone resistance, invasiveness, and metastatic potential in breast cancer.
Clarke R; Thompson EW; Leonessa F; Lippman J; McGarvey M; Frandsen TL; Brünner N
Breast Cancer Res Treat; 1993; 24(3):227-39. PubMed ID: 8435478
[TBL] [Abstract][Full Text] [Related]
7. The process of malignant progression in human breast cancer.
Clarke R; Dickson RB; Brünner N
Ann Oncol; 1990 Nov; 1(6):401-7. PubMed ID: 2083184
[TBL] [Abstract][Full Text] [Related]
8. Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice.
Manni A; Badger B; Martel J; Demers L
Cancer Lett; 1992 Sep; 66(1):1-9. PubMed ID: 1451091
[TBL] [Abstract][Full Text] [Related]
9. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
10. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.
Clarke R; Currier S; Kaplan O; Lovelace E; Boulay V; Gottesman MM; Dickson RB
J Natl Cancer Inst; 1992 Oct; 84(19):1506-12. PubMed ID: 1359153
[TBL] [Abstract][Full Text] [Related]
13. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.
Vickers PJ; Dickson RB; Shoemaker R; Cowan KH
Mol Endocrinol; 1988 Oct; 2(10):886-92. PubMed ID: 3185565
[TBL] [Abstract][Full Text] [Related]
14. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and oncogene mediated growth regulation of human breast cancer cells.
Kasid A; Lippman ME
J Steroid Biochem; 1987; 27(1-3):465-70. PubMed ID: 3501040
[TBL] [Abstract][Full Text] [Related]
16. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
18. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.
Clarke R; Brünner N; Katzenellenbogen BS; Thompson EW; Norman MJ; Koppi C; Paik S; Lippman ME; Dickson RB
Proc Natl Acad Sci U S A; 1989 May; 86(10):3649-53. PubMed ID: 2726742
[TBL] [Abstract][Full Text] [Related]
19. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
20. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
